LENZ Therapeutics, Inc. LENZ
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
LENZ Therapeutics, Inc. (LENZ) is a healthcare company listed in the US with a market value of about $130M. In the twelve months to September 30, 2026 it had revenue of $12M and net income of -$140M, a net margin of -1135.0%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -20%.
About LENZ Therapeutics
LENZ Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 1428% over three years (dilution for shareholders). It spends 98% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $12M | $19M | $0 | — | — | — | — |
| Net income | -$140M | -$82M | -$50M | -$70M | -$101M | -$71M | -$68M |
| Free cash flow | -$128M | -$70M | -$60M | -$60M | -$95M | -$59M | -$10M |
| EPS (diluted) | $-4.53 | $-2.85 | $-2.34 | $-35.71 | $-53.55 | $-71.30 | $-871.05 |
| Net margin | -1135.0% | -430.2% | — | — | — | — | — |
| ROIC | — | -25.2% | -22.5% | — | — | -12.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does LENZ Therapeutics pay a dividend?
Not currently.
Is LENZ Therapeutics a good stock to buy?
We do not give buy or sell advice. LENZ Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.